Abstract

**Background:** Multidrug resistance gene 1 (MDR-1) encodes for P-glycoprotein (P-gp) recognized for removing cytostatic drugs from tumor cells. MDR1 gene polymorphisms change function of P-gp. In this study, we are interested in investigating whether MDR1 C1236T single nucleotide polymorphisms (SNPs) affect the susceptibility and treatment-related toxicities in B-cell non-Hodgkin lymphoma (B-NHL) in the population of eastern China.

**Materials and methods:** A group of 107 B-NHL patients and 150 healthy donors, unrelated ethnic Han Chinese and residents of eastern China, were included in this study. The MDR1 C1236T polymorphisms were determined using polymerase chain reaction-allele specific primers after extraction of genomic DNA. Analyses were performed using SPSS and Arlequin software.

**Results:** MDR1 C1236T polymorphisms were not significantly related to the risk and treatment-related toxicities of B-NHL. A significant association between extranodal sites and C1236T allele was observed (C vs T: P=0.01).

**Conclusion:** Our findings could expand our understanding of MDR1 in B-NHL and provide references for further research in multidrug resistance.

Key words: B-cell non-Hodgkin lymphoma; multidrug resistance 1 (MDR1); polymorphism; treatment-related toxicities

Introduction

B-cell non-Hodgkin lymphoma (B-NHL) comprises a heterogeneous group of cancers and accounts for 85-90% of non-Hodgkin’s lymphoma (NHL) [1,2]. It was estimated that there were 81,560 new NHL cases and 20,720 deaths in the United States in 2021 [3]. These malignancies usually develop in the lymph nodes, but can involve any tissue in the body [1]. Patients present with painless lymphadenopathy, and a diverse of clinical symptoms dependent on the site of involvement [1,4]. Diagnosis of B-NHL is based on pathology of an excisional biopsy. The Ann Arbor classification is used to determine the stage of lymphoma [5]. The International Prognostic Index (IPI) and the age-adjusted International Prognostic index is used in predicting long-term survival for patients [6]. Main treatments for B-NHL are chemotherapy, immunochemotherapy, and radiation therapy [7-9]. However, most of these malignancies are refractory or relapsed after initial treatment.

Multidrug resistance gene 1 (MDR-1), also known as the adenosine triphosphate binding cassette B1 gene (ABCBI), is located on chromosomal region 7q21.1 [10]. MDR1 encodes for a transmembrane protein of 170 kD named P-glycoprotein (P-gp),
recognized and named for removing cytostatic drugs from tumor cells [10-13]. The function of P-gp is changed by MDR1 gene polymorphisms. Patients with these variants are at an increased risk of developing a variety of diseases and have different response to same treatment regimens [12]. To date, more than 50 single nucleotide polymorphisms (SNPs) of MDR1 have been described [14]. Among these reported SNPs, few studies focus on association between C1236T polymorphism and treatment-related toxicities in B-NHL.

In this study, we are interested in investigating whether MDR1 C1236T SNPs affect the susceptibility and treatment-related toxicities in B-NHL in the population of eastern China. Our findings could expand our understanding of MDR1 in B-NHL and provide references for further research in multidrug resistance.

Materials and methods

Subjects

A group of 107 B-NHL patients and 150 healthy donors were included in this study. All Subjects were unrelated ethnic Han Chinese, residents of Shanghai, Jiangsu and the surrounding regions. Patients were diagnosed based on pathology according to 2008 and 2016 World Health Organization (WHO) classification for tumors of hematopoietic and lymphoid tissues [15,16] from April 2014 to May 2020. Patients were excluded if they had concurrent cancer, severe cardiohepatic and renal dysfunction, severe cardiovascular and cerebrovascular disease, or they were during pregnancy or lactation. They were treated with R-CHOP or R-CHOP-like regimens as initial induction chemotherapy. Complete blood cell counts and toxicity assessments were performed after each cycle of chemotherapy. Hematologic toxicities (leukopenia, neutropenia, anemia and thrombocytopenia) were measured using the Common Terminology Criteria for Adverse Events version 3.0. The study adhered to the principles of the Helsinki Declaration.

Genotyping

Genomic DNA was extracted manually from peripheral blood. The MDR1 C1236T polymorphism was determined using the polymerase chain reaction-allele specific primers assay. Each polymerase chain reaction (PCR) reaction mixture contained: a PCR Master Mix reaction buffer (10 μl), DNA template (1 μl), primer (2 μl) and double distilled water (7 μl). For allele T, forward primer is 5-GTCACCTCAGTTACCCATCTCG-3 and reverse primer is 5-CTGCACCTTCAGGTCTCGG-3. For T/C, forward primer is 5-GTCACTCAGTTACCCATCTCG-3 and reverse primer is 5-GGTGATAGAGCCTCCTGGA TCA-3. The PCR conditions were 10 cycles of denaturation at 96 °C for 10 min, annealing at 58 °C for 30 min, and extension at 60 °C for 75 min, and 25 cycles of denaturation at 96 °C for 10 min, annealing at 55 °C for 30 min, and extension at 60 °C for 75 min. DNA fragments generated after restriction enzyme digestion were separated in a 2% agarose gel. The C1236T polymorphism of MDR1 was genotyped homozygous CC genotype, homozygous TT genotype and heterozygous CT genotype.

Statistical analysis

The Hardy-Weinberg equilibrium test was performed by Arlequin software 3.5. Associations between allele, genotype frequencies of MDR1 polymorphism and risk of B-NHL patients were determined using Binary logistic regression analysis. Pearson Chi-squared and Fisher’s exact test were used to analyze association between patients’ MDR1 polymorphism and clinical characteristics, treatment-related toxicities. All tests were two-sided and differences were considered significantly when p-value was <0.05. All analyses were performed using SPSS for Windows (version 26.0, SPSS, Chicago, IL, USA).

Results

Patient characteristics

The study consisted of 107 B-NHL patients. 56 were men and 51 were women. 52.3% patients were ≤60 years old. Clinical characteristics, including sex, age, staging, grouping, extranodal sites, ECOG score, LDH and IPI score, are shown in Table 1.

Hardy-Weinberg equilibrium examination

Table 2 shows examination of Hardy-Weinberg equilibrium of MDR1 SNPs (C1236T at rs1128503) in both B cell lymphoma groups and control groups. P value was >0.05. The SNPs of two groups were both in accordance with Hardy-Weinberg equilibrium.

Association between MDR1 polymorphisms and risk of B-NHL

To estimate the association between MDR1 polymorphisms and the risk of developing B-NHL, Binary logistic regression analysis was used. For MDR1 1236T allele, 70.1% were in patients and 64.7% in controls (OR=1.28, 95% CI=0.88-1.87, p= 0.2). For MDR1 1236CT genotype, 46.7% were in patients and 45.3% in controls (OR=2.00, 95% CI=0.78-5.11, p= 0.15), and for MDR1 1236TT allele, 46.7% were in patients and 42% in controls (OR=2.15, 95%
CI=0.84-5.53, \( p=0.11 \)). Analysis did not show any significant differences. Details are described in Table 3.

Table 1. Characteristics of 107 B-NHL patients in Eastern China

| Characteristics          | Number of patients (%) |
|--------------------------|------------------------|
| Sex                      |                        |
| Male                     | 56 (52.3)              |
| Female                   | 51 (47.7)              |
| Age (years)              |                        |
| ≤60                      | 56 (52.3)              |
| >60                      | 51 (47.7)              |
| Ann Arbor Staging        |                        |
| I-II                     | 40 (37.4)              |
| III-IV                   | 67 (62.6)              |
| Group                    | 81 (75.7)              |
| B                        | 26 (24.3)              |
| Extraneodal sites        |                        |
| 0-1                      | 76 (71.0)              |
| >1                       | 31 (29.0)              |
| Performance status (ECOG)|                        |
| 0-1                      | 85 (79.4)              |
| ≥2                       | 22 (20.6)              |
| Serum LDH                |                        |
| Normal                   | 74 (69.2)              |
| Elevated                 | 33 (30.8)              |
| IPI                      |                        |
| 0-2                      | 76 (71.0)              |
| 3-5                      | 31 (29.0)              |

B-NHL: B-cell non-Hodgkin lymphoma; ECOG: Eastern Cooperative Oncology Group; LDH: lactate dehydrogenase; IPI: international prognosis index.

Association between MDR1 polymorphisms and clinical characteristics of B-NHL

To evaluate the association between MDR1 polymorphisms and clinical characteristics of B-NHL, 107 B-NHL patients and 150 healthy people were enrolled. As shown in table 4, a significant association between extraneodal sites and C1236T allele was observed (C vs T: \( P=0.01 \)). It seemed that extraneodal sites were associated with C1236T genotype (CC vs CT vs TT: \( P=0.03 \)), \( p \) value was >0.05 adjusted by the Bonferroni method, however. No significant difference was found between MDR1 polymorphisms and other clinical characteristics (Table 4).

Table 2. Examination of Hardy-Weinberg equilibrium of MDR1 SNPs in both B-NHL patients group and control group

| Group          | Observed Heterozygosity | Expected Heterozygosity | SD  | \( P \) Value |
|----------------|-------------------------|-------------------------|-----|---------------|
| Patients (\( N=107 \)) | 0.47                    | 0.42                    | 0.00| 0.35          |
| Control (\( N=150 \))  | 0.45                    | 0.46                    | 0.00| 1.00          |

MDR1: Multidrug resistance gene 1; SNPs: single nucleotide polymorphisms; B-NHL: B-cell non-Hodgkin lymphoma; SD: standard deviation.

Association between MDR1 polymorphisms and treatment-related toxicities of B-NHL

We evaluated the association between polymorphisms and treatment-related toxicities among 107 B-NHL patients. The frequencies of major hematological toxicities after chemotherapy were compared between different alleles and genotypes of MDR1 C1236T. None of the MDR1 alleles and genotypes was associated with treatment-related toxicities (Table 5).

Table 3. Association between allele, genotype frequencies of MDR1 polymorphism and risk of B-NHL patients

| Groups          | Patients, n (%) | Controls, n (%) | OR  | 95% CI      | \( P \) Value |
|-----------------|-----------------|----------------|-----|-------------|---------------|
| Allele          |                 |                |     |             |               |
| C               | 64 (29.9)       | 106 (55.5)     | 1   | reference   | 0.20          |
| T               | 150 (70.1)      | 194 (46.7)     | 1.28| 0.88-1.87   |               |
| Genotype        |                 |                |     |             |               |
| 1236CC          | 7 (6.5)         | 19 (12.7)      | 1   | reference   |               |
| 1236CT          | 50 (46.7)       | 68 (45.3)      | 2.00| 0.78-5.11   | 0.15          |
| 1236TT          | 50 (46.7)       | 63 (42)        | 2.15| 0.84-5.53   | 0.11          |

MDR1: Multidrug resistance gene 1; B-NHL: cell non-Hodgkin lymphoma; OR: odds ratio; CI: confidence interval.

Discussion

Even to the same treatment, clinical courses and responses of different B-NHL patients are variable [4,17]. P-gp, encoded by MDR1 gene, plays an important role in regulating absorption, distribution, and elimination of drugs [18]. The genetic variation of MDR1 gene affects the pharmacokinetics of various drugs, resulting in changes in the efficacy and side effects of the drug [18,19]. Our study demonstrated that MDR1 C1236T polymorphisms were not significantly related to the risk and treatment-related toxicities of B-NHL. However, a significant association between extraneodal sites and C1236T allele was observed.

Up to now, relationship between MDR1 polymorphisms and a variety of diseases have been studied [20,21]. Previous study found that MDR1 Polymorphism at locus C1236T was not associated with the susceptibility of chronic lymphocytic leukemia [22], diffuse large B cell lymphoma [23] and multiple myeloma [24]. Here, our study verified that MDR1 C1236T is unrelated to the occurrence of B-NHL in eastern Chinese Han population. Hui He et al. found that intermediate-risk AML patients with TTT haplotype had a lower risk of relapse than those without TTT haplotype [25]. A possible reason is that the TTT haplotype is associated with a reduced P-gp expression, resulting to an increase in intracellular accumulation of chemotherapeutic agents [25]. Qing Chang et al. had analyzed that it had no significant relationship between C1236T polymorphism and susceptibility to hepatocellular carcinoma in 4 cohorts [26]. It seems that MDR1 polymorphisms at locus C1236T have no relationship with occurrence of cancer, but closely related to recurrence of malignant tumor.
Table 4. Association between clinical parameters and allele, genotype frequencies of MDR1 polymorphism in patients

| Characteristics     | Allele | P-Value | Genotype | P-Value | Pc |
|---------------------|--------|---------|----------|---------|----|
|                     | C      | T       |          | CC      | CT | TT |
| Gender              |        |         |          |         |    |    |
| Male                | 35 (31.3) | 77 (68.8) | 0.65 | 4 (7.1) | 27 (48.2) | 25 (44.6) | 0.95 |
| Female              | 29 (28.4) | 73 (71.6) | 3 (5.9) | 23 (45.1) | 25 (49.0) |        |
| Age                 |        |         |          |         |    |    |
| ≤60                 | 37 (33.0) | 75 (67.0) | 0.30 | 3 (5.4) | 31 (55.4) | 22 (39.3) | 0.18 |
| >60                 | 27 (26.5) | 73 (75.5) | 4 (7.8) | 19 (37.3) | 28 (54.9) |        |
| Ann Arbor Staging   |        |         |          |         |    |    |
| I-II                | 19 (23.8) | 61 (76.3) | 0.13 | 1 (2.5) | 17 (42.5) | 22 (55.0) | 0.28 |
| III-IV              | 45 (33.6) | 89 (66.4) | 6 (9.0) | 33 (49.3) | 28 (41.8) |        |
| Group               |        |         |          |         |    |    |
| A                   | 49 (30.2) | 113 (69.8) | 0.85 | 6 (7.4) | 37 (45.7) | 38 (46.9) | 0.79 |
| B                   | 15 (28.8) | 57 (71.2) | 1 (3.8) | 13 (50.0) | 12 (46.2) |        |
| Extraneal sites     |        |         |          |         |    |    |
| 0-1                 | 53 (34.9) | 99 (65.1) | 0.01 | 7 (9.2) | 39 (51.3) | 30 (39.5) | 0.03 |
| >1                  | 11 (17.7) | 51 (82.3) | 0 (0) | 11 (35.5) | 20 (64.5) |        |
| Performance status (ECOG) |         |         |          |         |    |    |
| 0-1                 | 49 (28.8) | 121 (71.2) | 0.50 | 6 (7.1) | 37 (43.5) | 42 (49.4) | 0.43 |
| ≥2                  | 15 (34.1) | 29 (65.9) | 1 (4.5) | 13 (59.1) | 8 (36.4) |        |
| Serum LDH           |        |         |          |         |    |    |
| Normal              | 46 (31.1) | 102 (68.9) | 0.57 | 6 (8.1) | 34 (45.9) | 34 (45.9) | 0.76 |
| Elevated            | 18 (27.3) | 48 (72.7) | 1 (3.0) | 16 (48.5) | 16 (48.5) |        |
| IPI                 |        |         |          |         |    |    |
| 0-2                 | 50 (32.9) | 102 (67.1) | 0.14 | 6 (7.9) | 38 (50.0) | 32 (42.1) | 0.38 |
| 3-5                 | 14 (22.6) | 48 (77.4) | 1 (3.2) | 12 (38.7) | 18 (58.1) |        |

Data are presented as n (%).  
MDR1: Multidrug resistance gene 1; Pc: P corrected; ECOG: Eastern Cooperative Oncology Group; LDH: lactate dehydrogenase; IPI: international prognostic index. The significant p value was bolded in this table.

Table 5. Association between allele, genotype of MDR1 polymorphism and hematological toxicities of patients

| MDR1 | Leukocytopenia | Neutropenia | Anemia | Thrombocytopenia | Concurrent infection |
|------|----------------|-------------|--------|------------------|---------------------|
|      | 0-II | III-IV | 0-II | III-IV | 0-II | III-IV | 0-II | III-IV | 0-II | III-IV | 0-II | III-IV | 0-II | III-IV |
| Allele |      |        |      |         |      |        |      |         |      |        |      |        |      |        |
| C     | 36 (56.3) | 28 (43.8) | 36 (56.3) | 28 (43.8) | 44 (68.8) | 20 (31.3) | 42 (65.6) | 22 (34.4) | 47 (73.4) | 17 (26.6) |
| T     | 86 (57.3) | 64 (42.7) | 70 (46.7) | 80 (53.3) | 102 (68.0) | 48 (32.0) | 90 (60.0) | 60 (40.0) | 103 (68.7) | 47 (31.3) |
| P Value | 0.88 | 0.19 | 0.91 | 0.44 | 0.49 |
| Genotype |      |        |      |         |      |        |      |         |      |        |      |        |      |        |
| 1236CC | 5 (71.4) | 2 (28.6) | 5 (71.4) | 2 (28.6) | 3 (42.9) | 4 (57.1) | 4 (57.1) | 3 (42.9) | 7 (100.0) | 0 (0.0) |
| 1236CT | 26 (52.0) | 24 (48.0) | 26 (52.0) | 24 (48.0) | 38 (76.0) | 12 (24.0) | 34 (68.0) | 16 (32.0) | 33 (66.0) | 17 (34.0) |
| 1236TT | 30 (60.0) | 20 (40.0) | 22 (44.0) | 28 (56.0) | 32 (64.0) | 18 (36.0) | 28 (56.0) | 22 (44.0) | 35 (70.0) | 15 (30.0) |
| P Value | 0.50 | 0.38 | 0.15 | 0.45 | 0.19 |

Data are presented as n (%).  
MDR1: Multidrug resistance gene 1.

Niveditha Muralidharan et al. showed that MDR1 3435C>T gene polymorphism influences adverse events to MTX in the South Indian cohort of patients with RA [27]. HYUN CHANG et al. suggested that the MDR1 genotypes at 2677 loci were associated with diarrhea in Korean advanced gastric cancer patients treated with paclitaxel-based chemotherapy [28]. These relevant findings were not found in our study. We found no significant relationship between MDR1 polymorphisms and treatment-related toxicities. These studies suggested that in different population, relationship between MDR1 polymorphisms and adverse events to different drugs is different. However, detailed mechanism was not yet clear.

In conclusion, we have investigated association between MDR1 C1236T polymorphisms and B-NHL in Han population of eastern China. Extraneal sites and C1236T allele is highly correlate, but no relationship was found between MDR1 SNPs and incidence or chemotheraphy-related toxicities of B-NHL. Unfortunately, our results are lack of complete follow-up records. Thus, no survival analysis was performed. Furthermore, we may complete data of follow-up. Besides, we might pay more attention on connection between MDR1 and relevant mRNA.

Acknowledgements

Funding

This study was supported by grants from Shanghai Sixth People’s Hospital Medical Group Project.

Ethics approval and consent to participate

The study protocol was approved by the Ethics
Committee of Shanghai Fengxian District Central Hospital. Informed consent was obtained from each patient and control.

Competing Interests

The authors have declared that no competing interest exists.

References

1. Armitage JO, Gascoyne RD, Lunning MA, et al. Non-Hodgkin lymphoma. Lancet. 2017; 390: 298-310.
2. Smalley KE, Hjallgrim H. Epidemiology and etiology of mantle cell lymphoma and other non-Hodgkin lymphoma subtypes. Semin Cancer Biol. 2011; 21: 293-8.
3. Siegel RL, Miller KD, Fuchs HE, et al. Cancer statistics, 2021. CA Cancer J Clin. 2021; 71: 7-33.
4. Wang XM, Bassig BA, Wen JJ, et al. Clinical analysis of 1629 newly diagnosed malignant lymphomas in current residents of Sichuan province, China. Hematol Oncol. 2016; 34:195-99.
5. Carbone PP, Kaplan HS, Musshoff K, et al. Report of the Committee on Hodgkin’s Disease Staging Classification. Cancer Res. 1971; 31:1860-1.
6. [No authors listed]. A predictive model for aggressive non-Hodgkin’s lymphoma. N Engl J Med. 1993; 329: 987-94.
7. Fuertes T, Ramiro AR, de Yebenes VG. miRNA-Based Therapies in B Cell Non-Hodgkin Lymphoma. Trends Immunol. 2020; 41:932-47.
8. Armitage JO. My treatment approach to patients with diffuse large B-cell lymphoma. Mayo Clin Proc. 2012; 87:161-71.
9. Monito S, Davies AJ, Matthews J, et al. Risk and clinical implications of transformation of follicular lymphoma to diffuse large B-cell lymphoma. J Clin Oncol. 2007; 25: 167-71.
10. García-Carrasco M, Mendoza-Pinto C, Marias Diaz S, et al. P-glycoprotein in autoimmune rheumatic diseases. Autoimmunity reviews. 2015; 14: 594-600.
11. Chen ML, Sun A, Cao W, et al. Physiological expression and function of the MDRI transporter in cytotoxic T lymphocytes. J Exp Med. 2020; 217: e20191388.
12. Pichianti-Diamanti A, Rosado MM, Scarsella M, et al. P-glycoprotein and drug resistance in systemic autoimmune diseases. Int J Mol Sci. 2014; 15: 4965-76.
13. Margier M, Le May C, Antoine T, et al. P-glycoprotein (ABCB1) is involved in vitamin K efflux. Food Chem. 2021; 343:128510.
14. Kimchi-Sarfaty C, Oh JM, Kim IW, et al. A “silent” polymorphism in the MDRI gene changes substrate specificity. Science. 2007; 315: 525-8.
15. Swerdlow SH, Campo E, Harris NL, et al. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Lyon, France: IARC; 2008.
16. Swerdlow SH, Campo E, Pileri SA, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood. 2016;127:2375-90.
17. Xiu B, Lin Y, Grote DM, et al. IL-10 induces the development of immuno-suppressive CD14(+)HLA-DR(low/-) monocytes in B-cell non-Hodgkin lymphoma. Blood Cancer J. 2015; 5: e328.
18. Zhao Y, Miao Z, Jiang M, et al. Effects of breviscapine and C3435T MDR1 gene polymorphism on the pharmacokinetics of fexofenadine, a P-glycoprotein substrate, in healthy volunteers. Xenobiotica. 2021; 51: 366-72.
19. Shen X, Cheng J. Effects ofMDR1(C3435T) Polymorphism on Resistance, Uptake, and Efflux to Antiepileptic Drugs. DNA Cell Bio. 2019; 38: 250-5.
20. Wang J, Liu Y, Zhao J, et al. P-glycoprotein gene MDRI polymorphisms and susceptibility to systemic lupus erythematosus in Guangxi population: a case-control study. Rheumatol Int. 2017; 37: 537-45.
21. Milojkovic M, Milacic N, Radovic J, et al. MDRI gene polymorphisms and P-glycoprotein expression in respiratory diseases. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2015; 159: 341-6.
22. Dong H, Miao K, Qiao G, et al. Polymorphisms and haplotypes in multidrug resistance 1 gene are not associated with chronic lymphocytic leukemia susceptibility and prognostic parameters of chronic lymphocytic leukemia in Chinese population. Leuk Lymphoma. 2011; 52: 1033-9.
23. Ni Y, Xiao Z, Yin G, et al. The single nucleotide polymorphism and haplotype analysis of MDRI in Chinese diffuse large B cell lymphoma patients. Biomed Pharmacother. 2015; 73:24-8.
24. Yin G, Xiao Z, Ni Y, et al. Association of MDRI single-nucleotide polymorphisms and haplotype variants with multiple myeloma in Chinese Jiangsu Han population. Tumor Biol. 2016; 37: 9549-54.
25. He H, Yin J, Li X, et al. Association of ABCB1 polymorphisms with prognostic outcomes of anthracycline and cytarabine in Chinese patients with acute myeloid leukemia. Eur J Clin Pharmacol. 2015; 71: 293-302.
26. Chang Q, He Z, Peng Y, et al. A meta-analysis of MDRI polymorphisms rs1128503 and rs1045642 and susceptibility to hepatocellular carcinoma. J Int Med Res. 2019; 47: 2800-9.
27. Muralidharan N, Antony PT, Jain VK, et al. Multidrug resistance 1 (MDR1) 3435C>T gene polymorphism influences the clinical phenotype and methotrexate-induced adverse events in South Indian Tamil rheumatoid arthritis. Eur J Clin Pharmacol. 2015; 71: 959-65.